机构：[1]Department of Breast Surgery, Fudan University Shanghai Cancer Center[2]Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[3]Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[4]Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China[5]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[6]Department of Breast Surgery, The First Hospital of Jilin University, Changchun City, Changchun, China[7]Xijing Hospital, The Air Force Military Medical University, Xi'an, China[8]Yuhuangding Hospital of Yantai, Yantai, China[9]Harbin Medical University Cancer Hospital, Harbin, China[10]Breast Disease Center, West China Hospital of Sichuan University, Chengdu, China四川大学华西医院[11]Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China[12]The Affiliated Hospital of Qingdao University, Qingdao, China[13]Guangdong Women and Children Hospital, Guangzhou, China[14]Zhongshan Hospital, Fudan University, Shanghai, China[15]Chongqing University Cancer Hospital, Department of Breast Cancer Center, Chonqqing, China[16]Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院[17]The Central Hospital of Wuhan, Wuhan, China
第一作者机构：[1]Department of Breast Surgery, Fudan University Shanghai Cancer Center[2]Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[3]Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China[4]Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China[6]Department of Breast Surgery, The First Hospital of Jilin University, Changchun City, Changchun, China[7]Xijing Hospital, The Air Force Military Medical University, Xi'an, China[8]Yuhuangding Hospital of Yantai, Yantai, China[9]Harbin Medical University Cancer Hospital, Harbin, China[10]Breast Disease Center, West China Hospital of Sichuan University, Chengdu, China[11]Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China[12]The Affiliated Hospital of Qingdao University, Qingdao, China[13]Guangdong Women and Children Hospital, Guangzhou, China[14]Zhongshan Hospital, Fudan University, Shanghai, China[15]Chongqing University Cancer Hospital, Department of Breast Cancer Center, Chonqqing, China[16]Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China[17]The Central Hospital of Wuhan, Wuhan, China
推荐引用方式(GB/T 7714)：
Tang Lichen,He Min,Wu Jiong,et al.Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Tang, Lichen,He, Min,Wu, Jiong,Wang, Zhonghua,Liu, Guangyu...&Shao Zhimin.(2023).Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Tang, Lichen,et al."Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学